Search

Displaying results 4631 - 4640 of 6198 in total
  1. Drug

    AVR-RD-02

    go.drugbank.com/drugs/DB17650
    Investigational

    AVR-RD-02 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.

  2. Drug

    D-glyceraldehyde 3-phosphate

    go.drugbank.com/drugs/DB02263
    Experimental

    An aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.

  3. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.

  4. Drug

    FS-1502

    go.drugbank.com/drugs/DB19287
    Investigational

    FS-1502 is an antibody-drug conjugate consisting of an anti-HER2 antibody, linker, and Monomethylauristatin F.

  5. Drug

    PAC-113

    go.drugbank.com/drugs/DB05756
    Investigational

    PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.

  6. Drug

    Porphobilinogen

    go.drugbank.com/drugs/DB02272
    Experimental

    It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.

  7. Drug

    Nitrous oxide

    go.drugbank.com/drugs/DB06690
    ApprovedInvestigationalVet approved

    It is known as "laughing gas" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug.

  8. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.

  9. Drug

    TT-232

    go.drugbank.com/drugs/DB12088
    Investigational

    Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).

  10. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.